Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009
A roadmap for management of chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 54 (4) 1901295; 10.1183/13993003.01295-2019 Year: 2019
Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2015; 24: 272-282 Year: 2015
Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2015; 46: 431-443 Year: 2015
The changing landscape of chronic thromboembolic pulmonary hypertension management Source: Eur Respir Rev, 26 (146) 170105; 10.1183/16000617.0105-2017 Year: 2017
ERS statement on chronic thromboembolic pulmonary hypertension Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension Year: 2021
C reactive protein level in pulmonary embolism. A marker of inflammatory processes in chronic thromboembolic pulmonary hypertension? Source: Eur Respir J 2007; 30: Suppl. 51, 602s Year: 2007
Chronic thromboembolic pulmonary hypertension Source: Eur Respir Mon 2012; 57: 108-118 Year: 2012
Frequency of chronic thromboembolic pulmonary hypertension screening after pulmonary embolism in cancer patients. Source: International Congress 2018 – Pulmonary embolism: long-term sequelae and advances in therapies Year: 2018
Vasodilator treatment in chronic thromboembolic pulmonary hypertension Source: Annual Congress 2003 - Update on chronic thromboembolic pulmonary hypertension Year: 2003
The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (3) 1801805; 10.1183/13993003.01805-2018 Year: 2019
Predicting recurrent pulmonary embolism and chronic thromboembolic pulmonary hypertension: one more way to skin the cat Source: Eur Respir J, 49 (5) 1700413; 10.1183/13993003.00413-2017 Year: 2017
A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006
Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020
The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 52 (3) 1800589; 10.1183/13993003.00589-2018 Year: 2018
Circulating microRNA signature and its novel involvement in pathogenesis of chronic thromboembolic pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012
Genetic diagnostics in patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2019 – Novel methods, diagnostics and biomarkers in chronic lung diseases Year: 2019
How does inflammation contribute to pulmonary hypertension? Source: Eur Respir J, 51 (1) 1702403; 10.1183/13993003.02403-2017 Year: 2018